KATO III
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
KATO III is a human gastric carcinoma cell line derived from the pleural effusion of a 55-year-old male patient. These cells exhibit a spherical morphology and predominantly grow in vitro while floating freely, displaying cytological characteristics of signet ring cells. Over prolonged culture periods, they gradually adhere to surfaces. With a population doubling time of approximately 36 hours, KATO III demonstrates tumorigenicity in the cheek pouches of anti-thymocyte serum-treated hamsters but not in nude mice. Importantly, KATO III cells are negative for p53 expression while being positive for CEA (carcinoembryonic antigen).
Why choose KATO III from AcceGen?
KATO III cells from AcceGen exhibit high viability and quality, ensuring reliable experimental results. They are provided in a sterile state and have been rigorously tested, confirming their negative status for bacteria, yeast, mycoplasma, HIV, HBV, and HCV. Additionally, their identity is verified using STR analysis, further enhancing their reliability and authenticity for research purposes.
| Product Code | Kato III; Kato-III; KATO-III; KATOIII; KatoIII; KATO 3 |
| Species | Human |
| Cat.No | ABC-TC0493 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Stomach |
| Disease | Gastric Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Gastric Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The KATO III cell line is a valuable tool in the realm of gastric carcinoma research, finding applications in various crucial areas. Its utility spans the screening of chemical compounds for their potential to induce apoptosis or cytotoxic effects specifically in human gastric carcinoma cells. Furthermore, KATO III cells are instrumental in investigating and identifying candidate drugs aimed at treating digestive gut cancer, with a particular focus on overcoming resistance to chemotherapeutic agents. This cell line plays a pivotal role in advancing our understanding of gastric cancer and developing more effective treatment strategies.
